There are a number of cancer vaccines in development for breast cancer, including but not limited to Lapuleucel-T (Dendreon), AE-37 (Antigen Express) and Stimuvax (Merck KgA). While these development candidates are aimed at a number of different targets, and AE-37 has published data in the HER2 breast cancer patient population, there is no guarantee that any of the these compounds will not in the future be indicated for treatment of low-to-intermediate HER2 breast cancer patients and become directly competitive with NeuVax.
Sentiment: Strong Sell
Well, Lapuleucel has a very long way to go still and Stimuvax failed it's P3 trial. AE-37 is also developed by Dr. Peoples, is behind NeuVax in development and didn't show results as good as NeuVax. But this is all beside the point. The market is massive for a vaccine of this type. As of now GALE will be the first in the market and capture the entire market share, if there is competition that will reduce GALE's market share, but at current valuation this really shouldn't be a consideration for investors. If this thing gets on the market our market cap will explode, regardless of competition.